Century Therapeutics, Inc. (IPSC) Dividend History

Company News

• CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain

  The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.

  GlobeNewswire Inc.

  Featured Companies: ACLX ALLO DTIL KYTX RNAC SANA
• Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders

  Century Therapeutics has entered into an agreement for an investigator-initiated Phase 1/2 trial of its CNTY-101 cell therapy in patients with B-cell mediated autoimmune diseases. The trial will be led by renowned experts and aims to evaluate the safety, efficacy, and translational data of CNTY-101 in various autoimmune conditions.

  GlobeNewswire Inc.
• Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer

  Century Therapeutics announced the appointments of Morgan Conn as Chief Financial Officer and Chad Cowan as Chief Scientific Officer. The company also announced that Hy Levitsky, President of Research and Development, will transition to an advisor role.

  GlobeNewswire Inc.
• Targeted Therapeutics Market is Pioneering Growth Towards a USD 118.6 Billion Milestone by 2031, with a CAGR of 6.4% - Exclusive Report by Transparency Market Research, Inc.

  The global targeted therapeutics market is expected to grow from $69.8 billion in 2023 to $118.6 billion by 2034, driven by the rise in cancer cases and the development of new targeted therapies.

  GlobeNewswire Inc.

  Featured Companies: BMY MRK PFE
• 5 Analysts Assess Century Therapeutics: What You Need To Know

  Across the recent three months, 5 analysts have shared their insights on Century Therapeutics (NASDAQ:IPSC), expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 2 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $13.6, a high estimate of $24.00, and a low estimate of $9.00. A decline of 2.86% from the prior average price target is evident in the current average. Investigating Analyst Ratings: An Elaborate Study An in-depth analysis of recent analyst actions unveils how financial experts perceive Century Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mitchell Kapoor HC Wainwright & Co. Maintains Buy $11.00 $11.00 Mitchell Kapoor HC Wainwright & Co. Lowers Buy $11.00 $13.00 Edward Tenthoff Piper Sandler Lowers Overweight $9.00 $10.00 Bill Maughan Canaccord Genuity Raises Buy $24.00 $22.00 Mitchell Kapoor HC Wainwright & Co. Maintains Buy $13.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related ...Full story available on Benzinga.com

  Benzinga